Alosetron: Ischemic colitis and serious complications of constipation

American Journal of Gastroenterology

Volumn 101, Issue 5, 2006, Pages 1080-1083

  Gallo Torres, Hugo ^a   Brinker, Allen ^a   Avigan, Mark ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; SEROTONIN 3 ANTAGONIST;

CLINICAL TRIAL; CONSTIPATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG MECHANISM; ENTERITIS; HUMAN; ISCHEMIC COLITIS; META ANALYSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEROTONIN RELEASE; SYSTEMATIC REVIEW;

CARBOLINES; COLITIS, ISCHEMIC; CONSTIPATION; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS; SEROTONIN ANTAGONISTS;

EID: 33646591887     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00650.x     Document Type: Review

References (20)

1. Gershon MD Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel Aliment Pharmacol Ther 1999 13 suppl 2 15 30
2. Tonini M Cipollina L DeGiorgio R et al Serotonergic drugs for the treatment of irritable bowel syndrome J Funct Syndr 2002 2 104 9
3. Talley NJ Current therapies. Irritable bowel syndrome remains a difficult condition to manage Drug Benefit Trends 2004 16 313 22
4. Baker DE Rationale for using serotonergic agents to treat irritable bowel syndrome Am J Health Syst Pharm 2005 62 700 13
5. Mayer EA Bradesi S Alosetron and irritable bowel syndrome. Drug evaluation Expert Opin Pharmacother 2003 4 2089 98
6. Chey WD Chey WY Heath AT et al Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome Am J Gastroenterol 2004 99 2195 203
7. Meeting of the International Foundation for Functional Gastrointestinal Disorders: Round Table Discussion on Ischemic Colitis. Participants included B Joelsson (Novartis; tegaserod), S Caras (Solvay; cilansetron), E Carter (GlaxoSmithKline; alosetron), KJ Rothman (Epidemiologist), LJ Brandt (Expert on Colon Ischemia), MD Gershon (Expert on 5-HT), and Hugo E Gallo-Torres (Chair), Milwaukee, WI April 9, 2005
8. Andresen V Hollerback S Reassessing the benefits and risks of alosetron. What is its place in the treatment of irritable bowel Syndrome? Drug Safety 2004 27 283 92
9. Brinker A Avigan M Epidemiology of ischaemic colitis (letter) Aliment Pharmacol Ther 2004 20 697 8
10. Scherl E Frissora CL Irritable bowel syndrome genophenomics: Correlation of serotonin-transporter polymorphisms and alosetron response Pharmacogenomics J 2003 3 64 8
11. Koch K Campanella C Baidoo CA et al Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Alosetron) Dig Dis Sci 2004 49 1244 9
12. Cole JA Cook SF Sands BE et al Occurrence of colon ischemia in relation to irritable bowel syndrome Am J Gastroenterol 2004 99 486 91
13. Higgins PDR Davis KJ Laine L Systematic review. The epidemiology of ischaemic colitis Aliment Pharmacol Ther 19 729
14. Loftus EV Sandborn WJ Tremaine WJ et al Incidence of ischemic colitis in Olmstead County, Minnesota. 1976-1998 Am J. Gastroenterol 2002 97 S12 S122 [Abstract 368]
15. Singh G Mithal A Triadafilopoulos G et al Patients with irritable bowel syndrome have a high-risk of developing ischemic colitis Gastroenterology 2004 126 A41 [Abstract]
16. El-Serag HB Pilgrim P Schoenfeld P Systemic Review: Natural history of irritable bowel syndrome Aliment Pharmacol Ther 2004 19 861 70
17. Chang L Chey WD Harris L et al Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: Systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006 101 1069 79
18. Kamm MA Review article: The complexity of drug development for irritable bowel syndrome Aliment Pharmacol Ther 2002 16 343 51
19. American College of Gastroenterology Functional Gastrointestinal Disorders Task force. Treatment effectiveness. Evidence-based position statement on the management of irritable bowel syndrome in North America Gastrointest Trends 2003 11 16
20. Holten KB Irritable bowel syndrome: Minimize testing, let symptoms guide treatment J Family Pract 2003 52 942 50